Biotechnology: keep an eye on new faces
Article Abstract:
Management changes in UK biotechnology companies are seen as important for investors. These companies often do not have sales and profit data to aid investors and it is their potential that is attractive, so the manager is crucial. Management changes include Pam Kirby who has moved to help sales and marketing at British Biotech and has come from Astra. This move makes British Biotech more attractive to fund managers. Meanwhile Cantab has appointed Jurek Sikorski as chief executive.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Biotechnology: bouncing babies
Article Abstract:
UK biotechnology companies are enjoying success. Chiroscience has set up an alliance with Pharmacia from Sweden to develop an anaesthetic, and this has led to a rise in Chiroscience's share price. The four biggest UK biotechnology companies are worth some 1.4 billion pounds sterling in 1995, while in 1991 there was not a single UK biotechnology company that was fully quoted. Biotechnology has been aided by developments in the pharmaceutical industry as a whole.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Biotechnology companies: out of fashion
Article Abstract:
UK biotechnology companies have become less popular with financial markets and this has affected the share prices of British Biotech, Chiroscience and Celltech. Cambrio has had to cancel a planned flotation. The shares of biotechnology firms had performed exceptionally well in 1st half 1996, but some companies have encountered failures in drug trials. The biotechnology sector is still likely to attract investors due to its importance for large drug firms.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Monoclonal expand into neural disorders. Ann Arbor community rallies in wake of Pfizer shutdown. Incretin mimetics vie for slice of type 2 diabetes market
- Abstracts: Managing your web developer: if styles don't mesh, technology can't save you. Firm fits businesses to online
- Abstracts: Pitching consumers through the business press. Mining a motherlode of information. BUYING INFLUENCERS TURN TO MAINSTREAM PUBLICATIONS: `PC MAGAZINE' RETAINS LEAD OVER `PC WORLD' IN CIMS RANKING
- Abstracts: Why a budget surplus is bad news. UK equities: loud and clear. Buoyed up
- Abstracts: Hong Kong: advance party. Hong Kong/Taiwan: double hit